Comparing Ipilimumab vs Tafinlar
Ipilimumab | Tafinlar |
|
---|
Ipilimumab | Tafinlar (dabrafenib) |
|
|||||||
---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Malignant Pleural Mesothelioma, Melanoma - Metastatic. ipilimumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Melanoma - Metastatic, Thyroid Cancer, Low-Grade Glioma, Non-Small Cell Lung Cancer, Solid Tumors. Tafinlar may also be used for purposes not listed in this medication guide. |
||||||||
More about Ipilimumab | More about Tafinlar (dabrafenib) | ||||||||
Ratings & Reviews | |||||||||
Ipilimumab has an average rating of 7.0 out of 10 from a total of 4 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 25% reported a negative effect. |
Tafinlar has an average rating of 7.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
Drug Class | |||||||||
Side Effects | |||||||||
See also: ipilimumab side effects in more detail. |
See also: Tafinlar side effects in more detail. |
||||||||
Generic Availability | |||||||||
N/A |
|||||||||
Pricing and Coupons * Prices are without insurance | |||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Tafinlar prices |
||||||||
Dosage Form(s) Available | |||||||||
N/A |
|
||||||||
Brand Names | |||||||||
Yervoy |
N/A |
||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||
352.8 hours |
22 hours |
||||||||
CSA Schedule ** View glossary of terms | |||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | |||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
Drug Interactions | |||||||||
A total of 152 drugs are known to interact with ipilimumab:
|
A total of 474 drugs are known to interact with Tafinlar:
|
||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
Disease Interactions | |||||||||
First Approval Date | |||||||||
N/A |
May 29, 2013 |
||||||||
WADA Class View World Anti-Doping Agency classifications. | |||||||||
N/A |
N/A |
||||||||
More Information | |||||||||
Patient resources | |||||||||
Professional Resources | |||||||||
Related Treatment Guide | |||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.